We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

73 hedge funds and large institutions have $2.33B invested in PMV Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 14

114% more capital invested

Capital invested by funds: $1.09B → $2.33B (+$1.25B)

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

43% more funds holding

Funds holding: 51 → 73 (+22)

12.77% more ownership

Funds ownership: 72.59% → 85.36% (+13%)

Holders
73
Holders Change
+22
Holders Change %
+43.14%
% of All Funds
1.29%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
36
Increased
19
Reduced
11
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$44.7M
2
BlackRock
BlackRock
New York
+$31.5M
3
Alkeon Capital Management
Alkeon Capital Management
New York
+$25.6M
4
ACA
Avoro Capital Advisors
New York
+$19.6M
5
PA
Perceptive Advisors
New York
+$11M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$13.4M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$12.8M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$10.9M
4
AG
Artal Group
Luxembourg
-$7.1M
5
UBS AM
UBS AM
Illinois
-$6.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$451M – – –
IVM
2
InterWest Venture Management
California
$398M – – –
EC
3
Euclidean Capital
New York
$257M +$164M +4,179,416 New
Viking Global Investors
4
Viking Global Investors
Connecticut
$145M -$10.9M -277,778 -11%
BC
5
Boxer Capital
California
$140M – – –
ACA
6
Avoro Capital Advisors
New York
$131M +$19.6M +500,267 +27%
RCM
7
RA Capital Management
Massachusetts
$105M – – –
BlackRock
8
BlackRock
New York
$82.7M +$31.5M +802,977 +148%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$79.2M -$13.4M -340,643 -21%
Vanguard Group
10
Vanguard Group
Pennsylvania
$71.3M +$44.7M +1,138,507 +5,693%
Alkeon Capital Management
11
Alkeon Capital Management
New York
$69.3M +$25.6M +652,151 +137%
PA
12
Perceptive Advisors
New York
$54.5M +$11M +280,000 +46%
Victory Capital Management
13
Victory Capital Management
Texas
$40.3M +$3.84M +97,866 +18%
RI
14
RTW Investments
New York
$30.8M +$34.6K +882 +0.2%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$26M +$432K +11,000 +3%
ACH
16
ArrowMark Colorado Holdings
Colorado
$24.1M -$290K -7,392 -2%
Invesco
17
Invesco
Georgia
$18.9M -$3.67M -93,491 -23%
Federated Hermes
18
Federated Hermes
Pennsylvania
$15.4M – – –
OCA
19
Octagon Capital Advisors
New York
$15.4M +$9.81M +250,000 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$15.1M +$8.35M +212,844 +645%
DCM
21
Driehaus Capital Management
Illinois
$14.3M -$225K -5,747 -2%
WP
22
Woodline Partners
California
$13.8M +$683K +17,400 +8%
State Street
23
State Street
Massachusetts
$12.8M +$8.14M +207,453 New
Franklin Resources
24
Franklin Resources
California
$12.3M +$275 +7 +0%
Principal Financial Group
25
Principal Financial Group
Iowa
$12.1M -$170K -4,345 -2%
1
2 3 4

PMVP Hedge Fund Activity: Q4 2020 in Review

73 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2020, worth a combined $2.33B — up 114% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PMVP positions and 14 closed out — a net gain of 22 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $44.7M. The largest seller was Wellington Management Group, cutting an estimated $13.4M.

  • 73 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2020, up from 51 in Q3 2020.
  • Funds reported $2.33B of PMV Pharmaceuticals stock for Q4 2020, up 114% quarter-over-quarter.
  • 36 funds opened new PMV Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +22 holders.
  • The largest PMV Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $44.7M added.
  • The largest PMV Pharmaceuticals seller in Q4 2020 was Wellington Management Group, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2020.